

# EXAMPLE OF A PHYSICIAN ORDER SET

PROVIDED FOR INFORMATION ONLY. SHOULD BE CUSTOMIZED PER  
INDIVIDUAL INSTITUTION POLICY

This order set **MUST** be used in combination with a standard sepsis admitting order set.  
(This set does not address admission, vital signs, diet, activity, etc.)

**NOTE: Per [institution name] P&T Committee GIAPREZA™ (angiotensin II) may only be ordered if the patient meets ALL of the following criteria:**

1. Adult patient (equal or greater than 18 years old) with septic or other distributive shock
2. Received adequate volume resuscitation
3. Receiving 1 or more vasopressors
4. Venous thromboembolism (VTE) prophylaxis (pharmacologic preferred, at minimum mechanical)

**Assessment: Include here assessment guidelines per your institution**

## **Administering GIAPREZA™ (angiotensin II) injection for intravenous infusion**

**GIAPREZA is dosed in nanograms/kg/min - 20 nanograms = 0.02 mcg**

IMPORTANT: Dilute GIAPREZA in 0.9% saline solution before use.

GIAPREZA can be mixed in 2 different infusion bag sizes corresponding to 2 different GIAPREZA concentrations: 250 mL (10 000 ng/mL of GIAPREZA) and 500 mL (5000 ng/mL of GIAPREZA).

The 250 mL bag may be used for fluid-restricted patients.

## **What to know when you start GIAPREZA:**

- Central venous line administration is recommended\*
- Monitor blood pressure response and titrate GIAPREZA every 5 minutes by increments of up to 15 ng/kg/min, as needed, to achieve or maintain target blood pressure
  - In the supporting clinical study, the median dose of GIAPREZA was 10 ng/kg/min at 30 minutes<sup>1</sup>
- Once the underlying shock has sufficiently improved, down-titrate every 5 to 15 minutes by increments of up to 15 ng/kg/min based on blood pressure
- During the first 3 hours, the maximum dose should not exceed 80 ng/kg/min.
- Maintenance dose should not exceed 40 ng/kg/min.

\* Administration via central line is recommended. If peripheral administration of GIAPREZA is needed, historically, the doses of angiotensin II given via a peripheral line were  $\leq 10$  ng/kg/min<sup>2</sup>, as a low concentration of 1 mL angiotensin II diluted in 1000 mL normal saline (0.9% sodium chloride [NS]). GIAPREZA should NOT be administered in the same peripheral line as other vasopressors. Blood pressure should be closely monitored.

GIAPREZA™ is marketed by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma LLC, its wholly owned subsidiary.

1. GIAPREZA (angiotensin II) [package insert]. San Diego, CA: La Jolla Pharmaceutical; 2017. 2. Data on file

PM-US-0209